2017 Q3 Form 10-Q Financial Statement
#000119312517251378 Filed on August 08, 2017
Income Statement
| Concept | 2017 Q3 | 2017 Q2 | 2017 Q1 |
|---|
Balance Sheet
| Concept | 2017 Q3 | 2017 Q2 | 2017 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $120.6M | $121.6M | $118.4M |
| YoY Change | -0.85% | -3.23% | 84.53% |
| Cash & Equivalents | $17.96M | $21.50M | $18.95M |
| Short-Term Investments | $102.6M | $100.1M | $99.49M |
| Other Short-Term Assets | $1.300M | $2.300M | $1.400M |
| YoY Change | 30.0% | 91.67% | 40.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $530.0K | $218.0K | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $122.4M | $124.2M | $119.9M |
| YoY Change | -0.22% | -2.26% | 83.88% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $970.0K | $1.010M | $984.0K |
| YoY Change | 24.68% | 17.72% | 6.38% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $4.200M | $15.00M | $31.20M |
| YoY Change | -58.0% | 6.38% | 2736.36% |
| Other Assets | $381.0K | $351.0K | $330.0K |
| YoY Change | 33.68% | 52.61% | 106.25% |
| Total Long-Term Assets | $5.555M | $16.36M | $32.52M |
| YoY Change | -49.86% | 7.4% | 1388.19% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $122.4M | $124.2M | $119.9M |
| Total Long-Term Assets | $5.555M | $16.36M | $32.52M |
| Total Assets | $127.9M | $140.5M | $152.4M |
| YoY Change | -4.34% | -1.23% | 126.19% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.353M | $1.375M | $819.0K |
| YoY Change | 61.07% | 168.03% | -36.71% |
| Accrued Expenses | $8.185M | $8.444M | $6.809M |
| YoY Change | 13.87% | 25.65% | 11.73% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $44.41M | $44.69M | $42.50M |
| YoY Change | 69.54% | 94.71% | 475.26% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $214.0K | $176.0K | $86.00K |
| YoY Change | 84.48% | 34.35% | -40.28% |
| Total Long-Term Liabilities | $214.0K | $176.0K | $86.00K |
| YoY Change | 84.48% | 34.35% | -40.28% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $44.41M | $44.69M | $42.50M |
| Total Long-Term Liabilities | $214.0K | $176.0K | $86.00K |
| Total Liabilities | $90.65M | $99.61M | $106.0M |
| YoY Change | 14.18% | 20.39% | 1307.98% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$328.9M | -$322.3M | -$313.1M |
| YoY Change | 9.84% | 10.25% | 10.88% |
| Common Stock | $366.2M | $363.3M | $359.5M |
| YoY Change | 3.52% | 3.28% | 5.06% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $37.30M | $40.92M | $46.32M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $127.9M | $140.5M | $152.4M |
| YoY Change | -4.34% | -1.23% | 126.19% |
Cashflow Statement
| Concept | 2017 Q3 | 2017 Q2 | 2017 Q1 |
|---|
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
48706809 | shares |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21925000 | |
| CY2017Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8444000 | |
| CY2017Q2 | us-gaap |
Assets Current
AssetsCurrent
|
124167000 | |
| CY2017Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
218000 | |
| CY2017Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
496000 | |
| CY2017Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
363291000 | |
| CY2017Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1375000 | |
| CY2017Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-113000 | |
| CY2017Q2 | us-gaap |
Assets
Assets
|
140527000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
113000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
135143000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
14999000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
135030000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
100145000 | |
| CY2017Q2 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
|
0 | Investment |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21500000 | |
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
48574985 | shares |
| CY2017Q2 | us-gaap |
Cash
Cash
|
1600000 | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
19886000 | |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
48574985 | shares |
| CY2017Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
48000 | |
| CY2017Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
34872000 | |
| CY2017Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
54745000 | |
| CY2017Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1622000 | |
| CY2017Q2 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2017Q2 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2017Q2 | us-gaap |
Liabilities
Liabilities
|
99612000 | |
| CY2017Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
140527000 | |
| CY2017Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
44691000 | |
| CY2017Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
375000 | |
| CY2017Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
351000 | |
| CY2017Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
176000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2304000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1010000 | |
| CY2017Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-322295000 | |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1972441 | shares |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
26079637 | |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
10424120 | shares |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.68 | |
| CY2017Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
40915000 | |
| CY2017Q2 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
16000 | |
| CY2017Q2 | ccxi |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
5951000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12823000 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8645000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
148691000 | |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
30205000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
421000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
356966000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
671000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-50000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
155872000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
51000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
121533000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
5997000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
121483000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
105740000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12024000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
48057920 | shares |
| CY2016Q4 | us-gaap |
Cash
Cash
|
2300000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
9746000 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
48057920 | shares |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
48000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
29019000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
67547000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2460000 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
105983000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
155872000 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
38335000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
282000 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
279000 | |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
101000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
722000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
905000 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-307059000 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1655524 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9345515 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.72 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49889000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
16000 | |
| CY2016Q4 | ccxi |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
5482000 | |
| CY2017Q1 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2100000 | |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
11157803 | shares | |
| us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company invests in a variety of financial instruments and, by its policy, limits the amount of credit exposure with any one issuer, industry or geographic area.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Accounts receivable are typically unsecured and are concentrated in the pharmaceutical industry and government sector. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies and government funded entities. The Company has not historically experienced any significant losses due to concentration of credit risk.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Accounts receivable consists of the following (in thousands):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="77%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June 30,<br /> 2017</b></td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31,<br /> 2016</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Vifor (International) Ltd. <sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">(1)</sup></p> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">218</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,000</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> U.S. Food and Drug Administration</p> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">205</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; break-inside: avoid" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">218</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,205</td> <td valign="bottom" nowrap="nowrap"> </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">  </p> </td> <td valign="bottom"> <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">  </p> </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="4%"> </td> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">As of December 31, 2016, accounts receivable excluded the additional $20.0 million cash commitment which is due from Vifor in December 2017 in connection with the CCX140 Agreement.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 125px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> As of June 30, 2017, accounts receivable excluded the remaining $30.0 million cash commitments due from Vifor, $20.0 million of which is due in December 2017 in connection with the CCX140 Agreement and $10.0 million of which is due in February 2018 in connection with the Avacopan Amendment. See Note 7, “Collaboration and License Agreements” for a detailed discussion.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">  </p> </div> | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
9476000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-15299000 | ||
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
33056000 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| us-gaap |
Depreciation
Depreciation
|
203000 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-06-30 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
ChemoCentryx, Inc. | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001340652 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8757000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-6949000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-29987000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
72000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-126000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
704000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1582000 | ||
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
653000 | ||
| us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
17167000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Description of Business</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. The Company’s principal operations are in the United States and it operates in one segment.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Unaudited Interim Financial Information</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2016 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s financial statements and the notes thereto included in the Company’s annual report on Form <font style="white-space:nowrap">10-K</font> for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 14, 2017.</p> </div> | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-3984000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
11988000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1472000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-15236000 | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | Segment | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15889000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
653000 | ||
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-63000 | ||
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | ||
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
297000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
76926000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
308000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
1769000 | ||
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
73250000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24299000 | ||
| us-gaap |
Revenue From Grants
RevenueFromGrants
|
0 | ||
| us-gaap |
Revenues
Revenues
|
17167000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4853000 | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y7M21D | ||
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.53 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
203247 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
6.86 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
1900000 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
6.53 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
1826538 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1546800 | shares | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
264948 | shares | |
| dei |
Trading Symbol
TradingSymbol
|
CCXI | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
48169 | shares | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div> | ||
| ccxi |
Amount From Grant
AmountFromGrant
|
500000 | ||
| ccxi |
Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
|
-206000 | ||
| ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
|
0 | shares | |
| ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
|
40208 | shares | |
| ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
|
-203247 | shares | |
| ccxi |
Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
|
Less than two years | ||
| ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Options Shares Authorized Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAuthorizedWeightedAverageExercisePrice
|
0 | ||
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
247000 | ||
| us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
2620000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-54301000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
55915000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
7488000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9849543 | shares | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
9102000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-25106000 | ||
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
28268000 | ||
| us-gaap |
Depreciation
Depreciation
|
173000 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.56 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7961000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
75380000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
175000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
70000 | ||
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
1878000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-162000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
400000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-25226000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-25473000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
247000 | ||
| us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
120000 | ||
| us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
95907000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
82000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
7000000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
488000 | ||
| us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
41688000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20307000 | ||
| us-gaap |
Revenue From Grants
RevenueFromGrants
|
175000 | ||
| us-gaap |
Revenues
Revenues
|
2795000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4641000 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
45031 | shares | |
| ccxi |
Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
|
124000 | ||
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9919000 | |
| CY2016Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
12939000 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.22 | |
| CY2016Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3877000 | |
| CY2016Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
161000 | |
| CY2016Q2 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
2620000 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9983000 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10144000 | |
| CY2016Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
161000 | |
| CY2016Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
64000 | |
| CY2016Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9062000 | |
| CY2016Q2 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
175000 | |
| CY2016Q2 | us-gaap |
Revenues
Revenues
|
2795000 | |
| CY2016Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2300000 | |
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
45785 | shares |
| CY2017Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-9269000 | |
| CY2017Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
18513000 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4184000 | |
| CY2017Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
336000 | |
| CY2017Q2 | us-gaap |
License And Services Revenue
LicenseAndServicesRevenue
|
8937000 | |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9240000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9576000 | |
| CY2017Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
336000 | |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-29000 | |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14329000 | |
| CY2017Q2 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
0 | |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
8937000 | |
| CY2017Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2500000 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
48224 | shares |
